Analyst Outlook | JMP Securities maintains a Market Outperform rating with a $7 price target, while other analysts adopt a cautious stance amid early-stage developments |
Market Potential | Explore RLYB116's target indications, representing a $5B market opportunity in rare diseases with limited competition and high unmet needs |
Financial Fortitude | With $46M cash runway into mid-2027, Rallybio demonstrates fiscal discipline amid pipeline transitions, boasting a strong current ratio of 9.98x |
Pipeline Pivot | Rallybio shifts focus to RLYB116, a C5 inhibitor, after discontinuing its lead FNAIT program, reshaping its development strategy and market position |
Metrics to compare | RLYB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRLYBPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.4x | −2.1x | −0.5x | |
PEG Ratio | −0.06 | −0.04 | 0.00 | |
Price / Book | 0.8x | 2.2x | 2.6x | |
Price / LTM Sales | 56.3x | 41.3x | 3.2x | |
Upside (Analyst Target) | −10.9% | 96.8% | 48.8% | |
Fair Value Upside | Unlock | 12.9% | 6.9% | Unlock |
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.